© 2 0 2 0 I n d I a n J o u r n a l o f P a t h o l o g y a n d M I c r o b I o l o g y | P u b l I s h e d b y W o l t e r s K l u W e r -M e d K n o W ABSTRACT Background: Metastasis associated colon cancer gene 1 (MACC1) is a gene that was first described as a c-Met transcription regulator causing the progression of colon cancer. In this study, protein and messenger RNA (mRNA) expression of MACC1 in breast cancer and its relationship with clinicopathological prognostic parameters were investigated. Methods: Sixty-six cases with tumors underwent radical mastectomy for invasive ductal carcinoma and 25 control cases operated for mammoplasty were included in the study. In paraffin blocks of tumor and control tissues, MACC1 expression was investigated by the immunohistochemical method and Real-time polymerase chain reaction (Real-Time PCR). In addition, vascular endothelial growth factor (VEGF) expression was examined immunohistochemically in tumor tissues. The relationship between MACC1 expression in tumor tissues, clinicopathological prognostic parameters, and VEGF was investigated. Results: In this study, protein and mRNA expressions of MACC1 were found to be higher in tumor tissues compared with normal breast tissues. MACC1 protein expression was also associated with significant poor prognostic markers, such as high histologic grade, ER negativity, and HER2 positivity. However, there was no correlation between MACC1 expression and VEGF. Conclusion: According to these results, MACC1 expression may be a marker of breast carcinoma as well as an independent predictor of poor prognosis. In addition, MACC1 may not affect angiogenesis in breast cancer or even if it has an effect, it may not be associated with VEGF. However, it would be appropriate to support these results in a larger series by investigating in vivo and in vitro studies.
INTRODUCTION
Metastasis Associated Colon Cancer Gene 1 (MACC1) was first described as a c-Met transcription regulator causing the progression of colon cancer and the main regulator of tumor progression and metastasis mediated by hepatocyte growth factor (HGF)/c-mesenchymal epithelial transition (MET) factor gene signaling in colon cancer. [1, 2] The HGF/c -Met pathway regulates various biological activities, including proliferation, motility, and invasion in cancer. [3] MACC1 shows higher expression in primary and metastatic colon cancer than normal colon mucosa and is associated with poor clinical course in colon cancer. [1] High expression of MACC1 after colon cancer has been associated with poor clinical course in many cancers. [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] However, the potential relationship between MACC1 expression and prognosis in breast cancer has not yet been fully explored.
In this study, MACC1 expression in invasive ductal carcinoma cases and normal breast tissues were examined by immunohistochemical and molecular methods, and the relationship between tumor expression and clinicopathological prognostic parameters was investigated. In addition, the relationship between MACC1 and vascular endothelial growth factor (VEGF) was evaluated to investigate the effect of MACC1 expression on angiogenesis.
Immunohistochemistry MACC1 and VEGF protein expressions in 66 tumors and 25 control tissues were studied by immunohistochemical method. First, approximately three 5-4µ thick sections were taken from the tumor paraffin blocks on a positively charged slide. Sections were kept in a 65°C incubator for 30-45 min and made ready for deparaffinization. Sections whose paraffin was partially removed were studied on Ventana BenchMark XT immunohistochemical staining device.
The immunohistochemical staining protocol was performed through the following steps: • Sections taken on positively charged slides were placed in the device (Ventana BenchMark XT) and the paraffin melting was performed • Antigen release was performed with Cell Conditioner 1 (CC1) solution on slides • Masking of endogenous peroxidase was performed by applying hydrogen peroxide to the slides and incubating for 7 min • Primary antibodies VEGF (Thermo Scientific RB-9031-R7-1: 100) and MACC1 (Millipore Polyclonal Human-Mouse Anti-MACC1-1: 400) were manually instilled and incubated for 30 min • Ultra View Universal DAB Detection kit secondary antibody was administered for 10 min • Background staining was performed with hematoxylin for 8 min and then conveyed with Bluing Reagent solution • After this stage, slides were removed from the device, rinsing, dehydration with alcohol, and clearing with xylene were performed. Entellan was dropped to the preparations and covered with lamella.
Interpretation of immunohistochemistry
Two pathologists evaluated the MACC1 and VEGF protein expressions, which were studied immunohistochemically, at 400x (40x objective lens, 10x ocular lens) with an ergonomic side-by-side light microscope (Nikon 300038) without any clinical and pathological information about the cases.
The degree of cytoplasmic staining in the epithelium of tumor cells was considered for both antibodies. Stromal areas were not evaluated. As both the antibodies showed expression in all of the tumor tissues but at different concentrations, the intensity of staining was considered while evaluating the expression. MACC1 [13] and VEGF [14] expressions were scored according to the staining intensity in the tissues as follows:
• If there is no staining-0 • If there is poor staining (light yellow)-1 • f there is moderate staining (yellow-brown)-2 • If there is strong staining (brown-3.
Statistical analysis was conducted by grouping the staining score as 0 and 1 as negative and 2 and 3 as positive.
Real-time PCR method
RNA isolation was performed using RNeasy FFPE (QIAGEN) kit from the paraffin blocks of 66 patients and 25 control patients according to user protocol. Complementary DNA isolation from RNA was performed in two steps using the kit (Gene All, Hyperscript first-strand synthesis kit, Cat no.: 601-005, Lot no.: FS015B04002). The Real-time PCR step was performed with the Applied Biosystem 7500 Fast Real-Time PCR instrument (GeneAllSybr Green Master Mix, Cat no.: 801-520, Lot no.: QP116G25001). Samples were studied in three replicates. Actin beta (ACTB) was used as control. Gene expression levels were measured using 7500 Fast Real-Time Sequence detection system Software (Applied Biosystems, Foster City, CA, USA). Gene expression was normalized to cycle threshold (CT) values by the 2-ΔΔCT method and ACTB, the internal control gene. [11, 15] The primers used in the study were as follows:
Ethics
In this study, the investigation protocol was in accordance with the Helsinki committee requirement and was approved by the Institutional Ethical Committee of The Balıkesir University School of Medicine (Decision no: 2017/41).
Statistics
Statistical analysis was performed using IBM Statistical Package for the Social Sciences (SPSS) software, v. 22.0 for Windows. In addition to descriptive statistics (mean, standard deviation [SD]), the Fischer Exact test was used for the immunohistochemical data and Pearson Chi-square test was used for the qualitative data. In the molecular data, student's t-test was used for comparison of independent groups. The results were evaluated at P < 0.05 significance levels.
RESULTS
In our study, there were 91 patients, including 66 tumor cases and 25 control cases. All the patients were females who had been operated for invasive ductal carcinoma. The mean age of the tumor patients was 57.4 ± 3 years while the mean age of the control patients was 39.7 ± 4 years. MACC1 protein expression and mRNA expression were evaluated in tumor and control cases.
Immunohistochemical findings MACC1 expression was positive in 45 (68.1%) whereas it was negative in 21 (31.8%) of the tumor cases [ Figure 1 ].
MACC1 expression score and number-% distribution in tumor cases are shown in Table 1 .
MACC1 expression was significantly higher in tumor cases (68.1%) than normal breast cases (40%) (P = 0.014). The MACC1 expression status of control and tumor tissues are presented in Table 2 and Figure 2 .
VEGF protein expression was positive in 53 tumor cases (80.3%) while it was negative in 13 cases (19.6%) [ Figure 3 ]. There was no significant relationship between MACC1 expression and VEGF expression in tumor cases (P = 0.31) [ Table 3 ].
COMPARISON OF MACC1 PROTEIN EXPRESSION WITH CLINICOPATHOLOGICAL PARAMETERS
MACC1 protein expression was compared with clinicopathological parameters in tumor cases; age (≤50, >50), tumor diameter (≤2 cm,>2 cm), lymph node metastasis (+,-), ER (+,-), PR (+,-), HER2 (+,-), Ki-67 (<15%, ≥15%), and histological grade of the tumor (Grade I-II, Grade III).
Figure 2: Relationship between MACC1 protein expression and tumor and control cases
The relationship between MACC1 protein expression and clinicopathological parameters in tumor cases is shown in Table 4 .
MACC1 protein expression was correlated with ER and HER2 status and grade, one of the prognostic parameters of the tumor. MACC1 expression was significantly higher in ER (-) cases compared with ER (+) cases (P = 0.02). Moreover, MACC1 protein expression was significantly higher in Grade III cases than in Grade I-II cases (P = 0.02). No correlation was found between MACC1 protein expression and other prognostic parameters such as age, tumor diameter, lymph node involvement, PR status, and Ki-67 proliferative index.
RT-PCR findings
mRNA expression of MACC1 measured by real-time PCR (qRT-PCR) was compared between tumor tissues and control tissues, between tumor groups with negative and positive MACC1 protein expression, and between tumor groups with VEGF (+) and VEGF (-) immunohistochemically [ Figure 4 ].
The mRNA expression of MACC1 was significantly higher in tumor tissues than in control tissues (P = 0.00). MACC1 mRNA expression was higher in the tumor group with positive MACC1 protein expression (P = 0.043). In VEGF (+) and VEGF (-) cases, MACC1 mRNA expression was very close to each other and there was no statistically significant difference (P = 0.779).
No statistically significant difference was found between the subjects in terms of mRNA expression depending on the status of prognostic parameters (patient age (≤50,>50), tumor diameter (≤2,>2), lymph node involvement (+,-), ER (+,-), PR (+, -), HER2 (+, -), Ki-67 proliferative index (≥ 15, <15), and Grade (Grade I-II and Grade III)), respectively (P = 0.888, P = 0.475, P = 0.340, P = 0.874, P = 0.550, P = 0.525, P = 0.792, P = 0.413) [ Figure 5 ].
DISCUSSION
RT PCR first identified MACC1 as a gene associated with poor prognosis. It acts as the main regulator of tumor growth and metastasis through the HGF/c-Met signal pathway in primary and metastatic tumors of the colon. [1, 2] High-MACC1 expression is associated with poor prognosis or survival in many cancers, such as lung cancer, [4, 5] gastric cancer, [12] hepatocellular carcinoma, [6] ovarian cancer, [7] cervical cancer, [8] endometrial cancer, [9] renal cell carcinoma, [10] and osteosarcoma. [11] In this study, parallel with the study of Huang et al. [13] on breast cancer, we found that MACC1 mRNA and protein expressions were correlated with each other and these two expressions were higher compared with normal breast tissue. In another study, investigating triple-negative breast cancer cases, a more aggressive form of breast cancer, similar results were obtained. In that study, immunohistochemical expression of MACC1 in tumor tissues was higher than in control tissues. [16] In a similar study conducted by measuring the serum MACC1 levels via enzyme-linked immunosorbent assay (ELISA) test, the serum MACC1 level was 
Figure 4: Expression levels of MACC1 mRNA in control and tumor cases (a) The relationship between MACC1 mRNA expression and MACC1 protein expression (b) The relationship between MACC1 mRNA expression and VEGF protein expression (c)
c b a found to be higher in breast cancer patients than in benign breast disease or healthy subjects. In addition, this study indicated the association of high-MACC1 levels in serum with short disease-free survival and a significant prognostic value in breast cancer. [17] However, MACC1 in serum might be high in other cancers, such as lung and colorectal cancers, and might not be specific to tissue expression for breast cancer.
ER positivity shows better clinical outcomes than ER negative patients for the ER receptor, an important prognostic marker of breast cancer. [18] In our study, it was found that the MACC1 protein expression was significantly higher in ER (-) cases compared with ER (+) cases. Prguda-Mujic et al. showed that MACC1 protein expression was correlated with ER, as well as shorter disease-free survival, in patients who did not receive adjuvant chemotherapy and had ER (+). [19] Furthermore, MACC1 expression was found to be positively associated with TNM staging of the tumor but not associated with ER, PR and HER2 status in the first study investigating the relationship between MACC1 and prognosis in breast cancer. [13] Huang et al. reported the prognostic value of MACC1 expression in both ER (+) and ER (-) breast cancer subgroups. Thus, it may be possible to benefit from new biomarkers such as MACC1 in determining the need for chemotherapy after complete resection for patients with ER (-) tumor. [13] HER2, a member of the receptor tyrosine kinase (RTK) family, is hyperactive in breast cancer and plays an important role in the onset and progression of the disease. [20] In this study, it was found that MACC1 protein expression was also associated with HER2 positivity and high tumor Grade, which are important poor prognostic markers as well as ER negativity. Muendlein et al. showed the association of MACC1 polymorphism with clinical outcomes in HER2 (+) breast cancer patients. [21] Lymph node involvement is one of the most important prognostic factors in disease-free and overall survival in breast cancer patients. According to the study conducted by Huang et al., MACC1 protein expression is associated with lymph node positivity. [13] Moreover, according to Han et al., there is a relationship between MACC1 expression and lymph node involvement in triple negative breast cancer. [16] In this study, we could not find this relationship. In another study conducted by Pruguda-Mujic et al. with 105 primary breast cancer patients, a negative correlation was found between high MACC1 expression and disease-free survival in patients with negative lymph node involvement. [19] Tumor Grade, another important prognostic parameter in our study, was positively correlated with MACC1 expression. However, Pruguda-Mujic et al. showed no relation between MACC1 and tumor Grade. [19] In the study of Han et al., MACC1 expression in triple-negative breast cancer was associated with lymph node involvement and TNM stages, but not with patient age, tumor diameter, location, type, or grades. [16] Therefore, although the number of studies to determine the prognostic role of MACC1 expression on breast cancer is few, there are different and conflicting results between MACC1 expression and prognostic markers (age, tumor diameter, lymph node involvement, ER, PR, HER2, histologic Grade, and TNM). [13, 17, 19] These differences in results may be because the tumor groups in the studies contain molecular and histological diversity and the studies have not yet been performed in a large series. This suggests that MACC1 should be investigated as an independent prognostic marker, apart from other prognostic markers.
VEGFA, also known as VEGF, is one of the most important endothelial growth factors involved in angiogenesis. Signaling mediated by VEGFA leads to angiogenesis by providing endothelial cell proliferation and migration. [22] Previous studies have shown increased VEGF expression in tumor tissue and it was significantly correlated with microvessel density and poor prognosis in many cancers including breast cancer. [14, 23] To investigate the effect of MACC1 on angiogenesis, the relationship between MACC1 and VEGF angiogenesis was investigated in various tumors. In studies conducted to date, MACC1 was found to be positively correlated with VEGF in gastric cancer [12] and cholangiocarcinoma, [22] and angiogenesis in cervical cancer. [8] However, as far as we can see, the effect of MACC1 on angiogenesis in breast cancer has not yet been investigated. Therefore, we aimed to investigate the effect of MACC1 on angiogenesis as a poor prognostic factor in breast cancer. However, we could not see the relationship between mRNA and protein expression of MACC1 and VEGF expression in breast cancer tissues. According to these results, MACC1 may not affect angiogenesis in breast cancer, or if this effect is present, it may not be related to VEGF.
In conclusion, we found that MACC1 mRNA and protein expression was higher in tumor tissues than normal breast tissues, and MACC1 protein expression was associated with significant poor prognostic markers such as high histological Grade, ER negativity, and HER2 positivity. Therefore, we think that MACC1 expression may be a therapeutic target by pointing to poor prognosis in addition to being a marker of breast carcinoma. Furthermore, we could not see the relationship between mRNA and protein expression of MACC1 and VEGF expression in breast cancer tissues. Accordingly, MACC1 may not affect angiogenesis in breast cancer or, even if the effect is present, it may not be associated with VEGF. Nevertheless, it would be appropriate to support these results in a larger series by investigating in vivo and in vitro studies.
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